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Abstract
Aims:Myopathy, characterized bymitochondrial oxidative stress, occurs in*10%of statin-treated patients, and a
major risk exists with potent statins such as rosuvastatin (Rvs). We sought to determine whether a peculiar
branched-chain amino acid-enriched mixture (BCAAem), found to improve mitochondrial function and reduce
oxidative stress in muscle of middle-aged mice, was able to prevent Rvs myopathy. Results: Dietary supple-
mentation of BCAAem was able to prevent the structural and functional alterations of muscle induced by Rvs in
youngmice. Rvs-increased plasma 3-methylhistidine (amarker ofmuscular protein degradation)was prevented by
BCAAem. This was obtained without changes of Rvs ability to reduce cholesterol and triglyceride levels in blood.
Rather, BCAAem promotes de novo protein synthesis and reduces proteolysis in cultured myotubes. Morpholo-
gical alterations of C2C12 cells induced by statin were counteracted by amino acids, as were the Rvs-increased
atrogin-1 mRNA and protein levels. Moreover, BCAAem maintained mitochondrial mass and density and citrate
synthase activity in skeletalmuscle of Rvs-treatedmice beside oxygen consumption andATP levels inC2C12 cells
exposed to statin. Notably, BCAAem assisted Rvs to reduce oxidative stress and to increase the anti-reactive
oxygen species (ROS) defense system in skeletal muscle. Innovation and Conclusions: The complex interplay
between proteostasis and antioxidant properties may underlie the mechanism by which a specific amino acid
formula preserves mitochondrial efficiency and muscle health in Rvs-treated mice. Strategies aimed at promoting
protein balance and controllingmitochondrial ROS levelmay be used as therapeutics for the treatment ofmuscular
diseases involving mitochondrial dysfunction, such as statin myopathy. Antioxid. Redox Signal. 25, 595–608.
Introduction
Statins (3-hydroxy-3-methylglutaryl-coenzyme A[HMG-CoA] reductase inhibitors) are currently the most
widely prescribed lipid-lowering drugs, and their use is ex-
pected to continue to grow alongside the increasing elderly
population and the diffusion of new guidelines on the treat-
ment of blood cholesterol (2013) of the American College of
Cardiology and American Heart Association (46).
Despite being relatively safe drugs, all statins are associ-
ated with a significantly elevated risk of myopathy, which
can range in severity from asymptomatic increases in crea-
tine kinase (CK) and muscle weakness, aches, and fatigue to
fatal rhabdomyolysis. While the incidence of rhabdomyo-
lysis is fortunately very low (0.1% of all statin users), the
number of patients who do not tolerate statins due to
myopathy-like symptoms is significant (1–10%) (12, 21, 44,
60). Although this represents a relatively small risk and al-
most certainly does not outweigh the benefits in cardiovas-
cular risk modification, the vast number of patients
prescribed or to be prescribed statin medication results in a
large absolute number of myopathic complications. Rosu-
vastatin (Rvs), the most prescribed brand name in the United
States, has a significantly higher risk of an abnormally raised
CK than other statins, including simvastatin, pravastatin, or
atorvastatin (64).
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Very intensive efforts, including the high-throughput
analysis, have been made; nevertheless, the mechanisms in-
volved in statin-induced myopathy are poorly understood
(35). Although statin-mediated lowering of cholesterol and
ubiquinone (coenzyme Q) or mitochondrial dysfunctions
have been widely investigated, no really efficacious aid for
statin toxicity was found so far (20, 22). These effects of
statins would predispose the myocytes to membrane alter-
ations, increased reactive oxygen species (ROS) production,
and apoptosis (10, 11, 21). Importantly, supplementationwith
coenzyme Q or antioxidants, such as selenium and vitamin E,
or other products targeting either cell respiration or oxidative
stress has been found scarcely effective (7, 8, 55).
Statins inhibit the mechanistic target of rapamycin
(mTOR) pathway that regulates protein synthesis and cell
growth in vascular smooth muscle (65, 66) and cancer cells
(25, 70). Accordingly, statins repress protein synthesis in
C2C12 myocytes (59) and increase proteolysis through the
atrogin system in skeletal muscles ofmouse and zebrafish (13,
30). In this study, we investigated the efficacy of a peculiar
formula of essential amino acids enriched in BCAAs to pre-
vent myopathy in mice treated with Rvs. The branched-chain
amino acid-enriched mixture (BCAAem) was previously
found to improve sarcopenia in elderly people, promote mi-
tochondrial biogenesis, and reduce ROS in culturedmyocytes
and skeletal muscles of middle-aged mice, through endothe-
lial nitric oxide synthase and mTOR pathways (16, 63). The
present results demonstrate that BCAAem supplementation
prevents the Rvs-induced structural and functional deterio-
rations of skeletal muscles in adult mice, without affecting the
cholesterol-lowering capability of the statin. These healthy
effects are accompanied by rescue of de novo protein syn-
thesis and decrease of proteolysis and mitochondrial dys-
function, with less oxidative stress. This suggests that dietary
supplementation of selective amino acid mixtures may be a
promising strategy to prevent statin myopathy in humans.
Results
BCAAem does not impair the cholesterol-lowering
capacity of Rvs
Dietary supplementation with BCAAem was found to
change selectively the levels of free amino acids in plasma, to
increase mitochondrial biogenesis, and to improve muscle
functions in sedentary and exercised middle-aged, but not
young, mice (15, 16). First, in the present work, we verified if
BCAAem supplementation influenced the ability of Rvs to
lower plasma lipid levels. Total cholesterol (T-Cho) and
triglycerides (TGs) were measured in 8-week-old male apo-
lipoprotein E gene-deficient (ApoE-KO) mice fed with a
high-fat diet (HFD) for 12 weeks (i.e., hyperlipidemic mice),
and then treated with Rvs, BCAAem, and Rvs plus BCAAem
for 1 month. Before HFD exposure, the T-Cho levels were
11.6 – 0.5mM and increased with time up to 50– 2.5mM.
When compared with untreated mice, Rvs reduced T-Cho
and TGs by about 35%– 5% and 41% – 6% (Fig. 1), as pre-
viously described (29, 37, 51). Notably, BCAAem, ineffec-
tive when administered alone, left unchanged the Rvs ability
to lower T-Cho and rather potentiated the effect of statin on
TG levels (Fig. 1). While not affecting daily food intake, Rvs
treatment significantly reduced mice body weight (BW)
(27.3 – 0.8 g in Rvs-treated vs. 30.9– 1.2 g in untreated mice;
p < 0.05). BCAAem did not affect BW either when admin-
istered alone or in combination with Rvs (data not shown).
BCAAem prevents Rvs myopathy
Next, young (2-month-old) C57BL/6JN mice (i.e., nor-
molipidemic mice) were used, and Rvs (20mg/kg/day) and
BCAAem (1.5 mg/g BW/day) were administered alone or
in combination for 1 month. BW, food intake, and water
consumption were unchanged after treatments with Rvs,
BCAAem, or Rvs plus BCAAem (Supplementary Table S1;
Supplementary Data are available online at www.liebertpub
.com/ars). Serum CK levels, a proxy for muscle damage
widely used as a biomarker of statin-induced myopathy (57),
were threefold higher in Rvs-treated than untreated mice
(Fig. 2A). BCAAem, unable to modify the enzyme levels
when administered alone,markedlyblunted the statin-increased
CK (Fig. 2A). Gross histology analysis by hematoxylin–eosin
(HE) staining did not showmajor changes of fiber architecture
and clear signs of cellular degenerative processes (i.e., calcifi-
cation, fibrosis, and necrosis) in gastrocnemius of treated mice
(Fig. 2B). Consistently, toluidine blue staining highlights nu-
merous irregular nuclei, with condensed chromatin, in gas-
trocnemius muscle of Rvs-treated animals differently from
mice exposed to statin and amino acid combination or untreated
FIG. 1. BCAAem supplementation does not interfere
with the plasma lipid-lowering capacity of Rvs in hyperli-
pidemic mice. Plasma T-Cho and TG of ApoE-KO mice
(n= 10/group) fedwithHFD for 12weeks and then treatedwith
Rvs and BCAAem alone or in combination for 4 weeks. Data
are reported as percentage expression over the untreated
mice. ***p< 0.001 versus untreatedmice. Data are represented
as mean–SEM. ApoE-KO, apolipoprotein E gene-deficient;
BCAAem, branched-chain amino acid-enriched mixture;
HFD, high-fat diet; Rvs, rosuvastatin; SEM, standard error of
the mean; T-Cho, total cholesterol; TG, triglyceride.
Innovation
Statin use in dyslipidemia is often hampered by unac-
ceptable side effects at the expense of skeletal muscle. In
the current study, we demonstrate that an amino acid for-
mula enriched in BCAAs is able to prevent muscular
damage induced by Rvs through induction of de novo
protein synthesis and decrease of protein breakdown. We
have also shown here that amino acids preserve mito-
chondrial efficiency and ameliorate the control of oxidative
stress in the statin-treated mice and muscle cells. Tailored
amino acid formulas may be exploited as potential thera-
peutics to preserve protein and mitochondrial homeostasis
in diseases such as statin myopathy.
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ones (Fig. 2B). These morphological aspects were further
investigated by transmission electron microscopy. The ul-
trastructural integrity of skeletal muscle fibers was com-
promised in Rvs, unlike Rvs plus BCAAem-treated animals;
muscle damage was restricted to the intracellular space of
individual fibers, predominantly affecting (swelling) the
triad structure (formed by T-tubule and sarcoplasmic retic-
ulum cisternae) typically located at the junction between A
and I bands of sarcomere, and the subsarcolemmal myofi-
brillar system (Fig. 2B). Disorganized mitochondria and
shrunken nuclei were evident in Rvs-treated animals, but
not in Rvs-treated mice supplemented with BCAAem. We
evaluated the effects on Rvs-myopathy, measured as CK
levels, toluidine blue staining, and electron microscopy of
different doses of BCAAem besides 1.5mg/g BW/day (i.e.,
0.15, 0.75, and 3.0mg/g BW/day). No statistically signifi-
cant effect was observed at the lower doses, while 3.0mg/g
BW/day was not superior to 1.5mg/g/day, as opposed to
statin damage (data not shown). Thus, we subsequently used
the last dose of BCAAem in all of the experiments carried
out in C57BL/6JN mice.
BCAAem preserves muscle function
in Rvs-treated mice
It is well known that statins cause a loss of skeletal muscle
mass paralleled by mitochondrial impairment (68). Although
muscle weight (MW) and MW relative to the BW were not
changed by Rvs (Supplementary Fig. S1A, B), we observed
that the fiber cross-sectional areas (CSAs) of vastus lateralis
and gastrocnemius muscle were reduced significantly in Rvs-
treated mice and these changes were prevented by BCAAem
supplementation (Fig. 3A). The MW and MW/BW ratio and
the CSA values were not changed by BCAAem supplemen-
tation per se (Fig. 3A and data not shown).
Next, to assess muscle function, we investigated whole
endurance capacity in vivo by means of horizontal and uphill
treadmill tests. Notably, starting at 10 days of treatment, Rvs
mice showed significantly lower time to exhaustion in both
treadmill tests compared with untreated animals (Fig. 3B, C).
On the contrary, the Rvs plus BCAAem mice showed higher
endurance capacity than Rvs mice at all time points, and their
performance was comparable with that of untreated at 20 and
30 days of treatment (Fig. 3B, C). No functional changes were
observed after BCAAem supplementation per se (Fig. 3B, C).
To confirm whether the observed changes of in vivo per-
formanceweremirrored by ex vivo changes in skeletal muscle
preparations, we measured both the absolute and normalized
tetanic forces and the rates of fatigue development in intact
tibialis muscle. The muscle absolute and normalized tensions
were lower in Rvs than Rvs plus BCAAem combination
(Fig. 3D, E).Moreover, Rvs induced a higher susceptibility to
fatigue than Rsv plus BCAAem or untreated (Fig. 3F). In-
terestingly, Rvs and Rvs plus BCAAem did not show any
functional effect on soleus muscle (data not shown).
BCAAem promotes de novo protein synthesis
and reduces proteolysis in cultured myotubes
Next, we sought to investigate the underlying mecha-
nism(s) of BCAAem effect on statin myopathy. Cultured
C2C12-derived myocytes were exposed to increasing Rvs
concentrations. Differently from vehicle treatment, 24 h
of Rvs treatment caused myocyte thinning and damage
(Fig. 4A and data not shown). This effect was detectable in a
range of Rvs concentrations superimposable to that observed
in plasma of Rvs-treated patients. Almost complete myocyte
loss was observed after 5 days of 50lM Rvs treatment (data
not shown). Importantly, yet unable to change myotube
FIG. 2. BCAAem supplementation protects muscle from
damage induced by Rvs. (A) Serum CK level measures
in mice (n = 20/group) treated for 1 month with Rvs and
BCAAem alone or in combination. The time course of CK
levels was evaluated at time 0 and after 10, 20, and 30 days
of treatment. The enzyme activity is expressed in U/L as
mean–SEM. *p< 0.05 versus untreated group; {p< 0.05 ver-
sus Rvs group. (B)HE staining did not showmajor changes of
fiber architecture and clear signs of cellular degenerative pro-
cesses in gastrocnemius muscle. Scale bar, 100lm. Toluidine
blue staining showed that although the organization of sarco-
meres appeared regular, nuclei appeared strongly wavy shaped
(arrow), with condensed chromatine on the inner surface of
nuclear envelope and inside the nuclear matrix. BCAAem
supplementation prevented these nuclear alterations. Scale bar,
10lm. TEM analysis showed that Rvs treatment did cause
irregular nuclei with condensed chromatin near the inner nu-
clear membrane. The perinuclear cytoplasm had wide empty
spaces (arrows), scarce and small mitochondria with dilated
cristae, and little electron-dense matrix. Rvs plus BCAAem
treatment prevented thesemorphological damages andpreserved
nuclear morphology, although mitochondria (arrowheads)
tended to be smaller compared with untreated and BCAAem-
treated mice. N, nucleus. Scale bar: 1 nm. Analyses were
performed in two animals per group. Representative stained
images from at least three independent experiments are re-
ported. All experiments were conducted in C57BL/6JNmice.
CK, creatine kinase; HE, hematoxylin–eosin. To see this
illustration in color, the reader is referred to theweb version of
this article at www.liebertonline.com/ars
PREVENTION OF STATIN MYOPATHY WITH DIETARY AMINO ACIDS 597
morphology when added alone, BCAAem robustly antago-
nized the morphological effects of statin (Fig. 4A).
Since it is known that amino acids are able to modulate
protein synthesis and degradation in muscle (41), we inves-
tigated whether BCAAemwas able to counteract the effect of
Rvs on these processes. According to Tuckow et al. (59),
treatment of C2C12 myotube cultures with Rvs for 24 h re-
sulted in significant reduction of de novo protein synthesis,
which was prevented by BCAAem (Fig. 4B). BCAAem alone
left unchanged de novo protein synthesis compared with
vehicle-treated cells (Fig. 4B).
Plasma 3-methylhistidine (3-MeH) is considered a marker
of protein degradation in skeletal muscle (28). We measured
the circulating 3-MeH levels in mice, and we found that
BCAAem counteracted the Rvs-increased proteolysis (Sup-
plementary Fig. S2). Next, we measured rates of protein
breakdown in Rvs-treated myotubes. Similarly to what was
observed with lovastatin treatment (30), we found that Rvs
treatment time- and concentration-dependently increased
atrogin-1 mRNA levels in C2C12 myocytes (Fig. 5A). Par-
ticularly, myocyte exposure to 50 lM Rvs significantly in-
duced atrogin-1 expression after 6 h and caused a threefold
induction after 48 h (Fig. 5B). As shown in Figure 5C, also
atrogin-1 protein levels were increased 2.5-fold after 48 h of
Rvs exposure. BCAAem, which had no effects when added
alone, counteracted the atrogin-1 mRNA and protein levels
increased by Rvs (Fig. 5B, C). Together, these experiments
suggest that the amino acid mixture counterbalanced Rvs-
induced muscle injury through the modulation of de novo
protein synthesis and breakdown.
Rvs and BCAAem modulate BCAA metabolism
Protein turnover is linked to catabolism of BCAAs (i.e.,
leucine, isoleucine, and valine) (34) and themost active system
for the oxidation of BCAAs is located in skeletal muscle (52).
Thus, we investigated the expression and activity of mito-
chondrial branched-chain aminotransferase (BCATm) and
branched-chain a-keto acid dehydrogenase (BCKDH), the first
two enzymes of BCAA degradation. Increased expression of
BCKDH, but not of BCATm, was observed in vastus lateralis
muscle after treatment with Rvs, alone or in combination with
BCAAem (Fig. 6A and Supplementary Fig. S3A). Accord-
ingly, a robust increase of BCKDH activity, unlike BCATm,
was observed in C2C12 cells exposed to 50lM Rvs (Fig. 6B
and Supplementary Fig. S3B). A concomitant treatment with
BCAAem further activated the enzyme (Fig. 6B). Predictably,
amino acids were effective per se when added alone on
BCKDH, unlike BCATm, levels and activity (Fig. 6A, B and
Supplementary Fig. S3A, B). As the BCKDH activity is at-
tenuated byBCKDH kinase (BCKDK) that phosphorylates the
enzyme (52), we assessed the expression of BCKDK. No
changes of theBCKDKmRNAlevels in vastus lateralismuscle
were induced by treatments with Rvs, amino acids, or their
combination in muscle (Fig. 6C) and C2C12 cells (data not
FIG. 3. BCAAem supplementation restores skeletal
muscle function and structure in Rvs-treated mice. (A)
Fiber CSA of gastrocnemius and vastus lateralis muscle. (B)
and (C) Initial time to reach the exhaustion following hori-
zontal and uphill treadmill tests as expression of endurance
capacity of mice at time 0 and after 10, 20, and 30 days of
treatments. (D) and (E) Absolute (g) and normalized tetanic
forces over muscle volume expressed in microliters (g/ll)
were evoked by 110Hz for 500ms. (F) Fatigue index in intact
tibialis muscle, measured as the tetanic force drop after dif-
ferent stimulation frequencies (from 0.03 to 0.9Hz, 500ms)
compared with the maximal tetanic force and expressed as %
over untreatedmice. All data were obtained fromC57BL/6JN
mice treated with Rvs and BCAAem alone or in combination
for 1 month (n = 20/group). **p < 0.01, ***p < 0.001 versus
corresponding untreated mice. Data represent mean – SEM.
CSA, cross-sectional area.
FIG. 4. BCAAem supplementation antagonized the
damage induced byRvs through themodulation of de novo
protein synthesis in C2C12 myotubes. (A) Morphological
changes of C2C12 myotubes after 24 h of treatment with Veh
or Rvs (50lM) with or without BCAAem (the images are
representative of five separate experiments). (B) De novo
protein synthesis was expressed as percentage over vehicle-
treated cells exposed. C2C12 myotubes were exposed to Rvs
(10 or 50lM) and BCAAem (1 · ) alone or in combination for
24 h (n = 5 experiments).*p< 0.05 versus vehicle-treated
cells; {p < 0.05 versus Rvs-treated cells. All data represent
mean – SEM. Veh, Vehicle.
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shown). Thus, the increased BCKDH activity observed with
Rvs and Rvs plus BCAAem seems to be linked to its increased
expression.
BCAAem prevents mitochondrial defects
Given the role of mitochondria dysfunction in the statin-
induced myopathy development (32, 53) and the ability of
BCAAem to boost mitochondrial activity (16), we asked
whether amino acid supplementation could rescue Rvs myo-
pathy by acting on mitochondria. Thus, citrate synthase (CS)
activity was measured both in skeletal muscles and C2C12
myocytes. The CS activity was found robustly decreased in
gastrocnemius and tibialis muscles of Rvs-treated mice com-
pared with untreated ones (Fig. 7A). BCAAem fully restored
the enzyme activity in Rvs mice without changing it in the
Rvs-untreated mice (Fig. 7A). To confirm further that the ef-
fects of BCAAem were due to increased oxidative, but not
glycolytic, metabolism, we measured lactate dehydrogenase
activity. No marked changes were found in the Rvs and Rvs
plus BCAAem-treated mice compared with untreated mice in
all muscles studied (data not shown), confirming that oxidative
metabolism is the major biochemical target of amino acids
(17). Accordingly, the mitochondrial mass and density, which
were markedly reduced in gastrocnemius of the Rvs-treated
mice, were restored to values of untreated mice by BCAAem
(Fig. 7B, C). BCAAem was unable to affect mitochondrial
mass and density in skeletal muscle of Rvs-untreated mice.
The observed in vivo effects on mitochondria were con-
firmed in vitro in C2C12 myocytes. Notably, BCAAem was
able to improve mitochondrial function by increasing mito-
chondrial respiration and oxidative phosphorylation (Fig. 7D,
E) and restoring full ATP production (Fig. 7F). Collectively,
these findings support the idea that Rvs-induced myopathy
would derive from defective oxidative metabolism and that
the BCAAem supplementation would oppose to it acting on
mitochondrial efficiency.
BCAAem assists Rvs to reduce oxidative stress
As one consequence of mitochondrial dysfunction and cause
of oxidative damage is the accumulation of ROS (61), we
studied different ROS markers in vastus lateralis muscle after
Rvs and BCAAem treatment. When compared with untreated
animals,mitochondrialH2O2 releasewas increased,while basal/
total aconitase activity ratio was decreased by Rvs (Fig. 8A, B).
These differences were less pronounced following contempo-
rary supplementation of BCAAem (Fig. 8A, B). On the other
hand, Rvs reduced lipid peroxidation in vastus lateralis muscle,
and BCAAem strengthened this reduction (Fig. 8C). Accord-
ingly, the amount of 8-hydroxy-2¢-deoxyguanosine (8-OHdG),
a marker of oxidative DNA damage, was reduced in both mi-
tochondrial and nuclear DNA from vastus lateralis of Rvs-
treated mice; this effect was boosted by BCAAem, which was
ineffective when administered alone (Fig. 8D).
Moreover, also the alternative ROS-producing system
NADPH oxidase was found to play some, yet limited, role. In
fact, p47phox (cytosolic NADPH oxidase) (26) mRNA was
decreased by BCAAem in vastus lateralis muscle of Rvs-
treated mice, even if gp91phox and Rac1 (membrane NADPH
oxidase) mRNA levels were unchanged, as confirmed by
protein level analysis (Supplementary Fig. S4A, B).
Because oxidative stress ignites the anti-ROS defense
system, we investigated the expression of anti-ROS enzymes
in gastrocnemius of statin- and/or amino acid-treated mice.
Superoxide dismutase 1 and 2 (SOD1 and SOD2) and cata-
lase mRNAs and proteins were increased by Rvs when
compared with untreated mice and these increases were
strengthened by BCAAem, ineffective when supplemented
alone (Fig. 8E). Furthermore, given that cells respond to
oxidative stress by activating the mitochondrial unfolded
protein response (UPRmt), which induces genes that promote
ROS detoxification (36), we found a robustly increased
FIG. 5. BCAAem supplementation normalized atrogin-1
gene expression in Rvs-treated myotubes. Atrogin-1
mRNA was analyzed by means of quantitative RT-PCR.
GAPDH was served as the standard. (A) Dose and time
course analysis of atrogin-1 mRNA levels. (B) C2C12
myotubes were treated with 50lM Rvs for 6, 24, 36, and
48 h, with or without BCAAem (1·) for 24 h. Relative ex-
pression value of the vehicle-treated cells was taken as 1.0
(n = 5 experiments). (C) Atrogin-1 protein levels detected by
immunoblot in C2C12 myotubes treated with 50lM Rvs
and BCAAem (1· ) for 48 h. One experiment representative
of three reproducible ones was shown, with relative values
of densitometric analysis referred to the vehicle-treated cells
taken as 1.0. GAPDH was the loading control. *p < 0.05,
**p < 0.01 versus vehicle-treated cells; {p < 0.05 versus Rvs-
treated cells. All data are expressed as mean – SEM.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RT-
PCR, reverse transcriptase–polymerase chain reaction.
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expression of CLPP and heat shock protein 60 (HSP60)
proteins associated with UPRmt in Rvs and, particularly, in
Rvs plus BCAAem relative to untreated C2C12 myocytes
(Fig. 8F). Amino acids alone were ineffective to change the
UPRmt marker expression. Collectively, these results suggest
that Rvs, while impairing mitochondrial function with ROS
production, promotes antioxidant defense systems, which are
insufficient to prevent muscle toxicity. Notably, BCAAem
supplementation exerts a coordinated antioxidant effect,
which boosts the antioxidant action of Rvs.
FIG. 6. BCAAem supplementation alone or in combination with Rvs stimulates BCKDH in muscle. (A) and (C) BCKDH
andBCKDKmRNA(top) andprotein levels (bottom) in vastus lateralismuscle ofC57BL/6JNmice treatedwithRvs andBCAAem,
alone or in combination (n=5 experiments performed in 8–10 animals/group). mRNA levels were analyzed by means of quanti-
tative RT-PCR. GAPDH was served as the standard. Relative expression values of the untreated mice were taken as 1.0. Protein
levels were analyzed bymeans of immunoblot. One experiment representative of three reproducible ones was shown, with relative
values of densitometric analysis referred to the vehicle-treated cells taken as 1.0. GAPDH was the loading control. (B) BCKDH
activity measured in C2C12 myotubes exposed to BCAAem (1· ) for 24 h alone or in combination with Rvs (50lM) added to
cell culture for 15 or 30min (n= 5 experiments). *p<0.05, ***p< 0.001 versus vehicle-treated cells; {p< 0.05 versus Rvs-treated
cells. All data are expressed as mean–SEM. BCKDH, branched-chain a-keto acid dehydrogenase; BCKDK, BCKDH kinase.
FIG. 7. BCAAem supplementation prevents myopathy induced by Rvs boosting mitochondrial function. (A) CS
activity in gastrocnemius and tibialis muscles. (B) Mitochondrial area/cytosol area ratio and (C) number of mitochondria
per 100lm2 of cytoplasm, analyzed by electron microscopy in gastrocnemius of mice treated with Rvs and BCAAem (n= 5
experiments performed in 8–10 mice/group). All experiments were conducted in C57BL/6JN mice. *p< 0.05 and
***p< 0.001 versus corresponding untreated animals; {p < 0.05 versus corresponding Rvs animals. (D) CS activity, (E)
oxygen consumption, and (F) ATP levels in C2C12 myotubes treated with BCAAem (1 · ) for 24 h with or without Rvs
(50 lM). ATP was expressed as fold change versus untreated cells taken as 1.0 (n = 5 experiments). *p < 0.05 versus vehicle-
treated cells; {p < 0.05 versus Rvs-treated cells. All data represent mean – SEM.
600 D’ANTONA ET AL.
Discussion
Our data demonstrate that dietary supplementation of
BCAAem preserved structure and function of skeletal muscles
in mice exposed to chronic treatment with Rvs, without im-
pairing the ability of this drug to lower plasma cholesterol
levels. These healthy effects were accompanied both by rescue
of de novo protein synthesis and reduction of protein break-
down. Moreover, the amino acid formula improved mito-
chondrial dysfunction of skeletal muscles in the Rvs mice and
strengthened the anti-ROS defense mechanisms of statin, with
efficacious prevention of oxidative stress in muscle. Although
skeletal muscle is a complex tissue comprising a variety of
functionally diverse fiber types differently sensitive to statins,
we carried out a series of experiments in different muscles (as
summarized in Supplementary Table S2) aimed to investigate
overall protective mechanisms of BCAAem supplementation
without any a priori hypothesis. Notably,Westwood et al. (69)
found a continuum of fiber sensitivity (i.e., necrosis) to high
dose of Rvs (150mg/kg/day), that is, least sensitive, I < IIA <
IID < IIB, most sensitive, and that mirrors their oxidative/
glycolytic metabolic properties. Rvs did not induce necrosis in
the soleus muscle, which contains predominately slow oxi-
dative type I and the more oxidative of the fast fibers, IIC and
IIA. Accordingly, we did not observe any functional effects of
Rvs and BCAAem on soleus muscle (data not shown).
That BCAAem counteracted reduction of de novo protein
synthesis and renormalized protein lysis induced by Rvs in
C2C12 myotubes is particularly important because the
muscle-specific ubiquitin ligase atrogin-1/MAFbx has been
found recently to mediate lovastatin-induced muscle toxicity
in human, zebrafish, and rodent skeletal muscle (30).
A central regulator of proteostasis is mTOR, a serine/
threonine protein kinase that regulates many cellular activi-
ties besides protein balance, including autophagy, prolifera-
tion, survival, and energy metabolism (23). In accord with
FIG. 8. BCAAem supplementation coordinates an antioxidant effect. (A) Mitochondrial H2O2 release, (B) basal
aconitase/total aconitase ratio, (C) lipid peroxidation measured as MDA production, and (D) nDNA and mtDNA oxidative
damage measured as 8-OHdG production in vastus lateralis muscle of Rvs and BCAAem-treated mice (n = 3 experiments).
(E) SOD1, SOD2, and catalase mRNA and protein levels detected by immunoblot in gastrocnemius muscle. mRNA was
analyzed by means of quantitative RT-PCR, relative expression values of untreated mice were taken as 1.0 (n = 3 exper-
iments), and GAPDH was served as the standard. *p < 0.05, ***p < 0.001 versus untreated mice; {p< 0.05 versus Rvs-treated
mice. All experiments were performed in 8–10 C57BL/6JN mice per group and represent mean – SEM. (F) HSP60 and
CLPP proteins detected by immunoblot in C2C12 myotubes treated with Rvs (50lM) and BCAAem (1 · ) for 24 h. One
experiment representative of five reproducible ones is shown for Western blot images, with values of densitometric analysis
referred to GAPDH as a loading control. *p < 0.05 versus vehicle-treated cells; {p < 0.05 versus Rvs-treated mice. Data
are expressed as relative values versus control taken as 1.0 and reported as mean – SEM. 8-OHdG, 8-hydroxy-2¢-
deoxyguanosine; CLPP, caseinolytic peptidase ATP-dependent proteolytic subunit homolog; HSP60, heat shock protein 60;
MDA, malondialdehyde; mtDNA, mitochondrial DNA; nDNA, nuclear DNA; SOD, superoxide dismutase.
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several evidences (9, 66), we have observed that Rvs in-
hibited mTOR activity, measured as Ser2448-mTOR and
Thr389-S6K phosphorylation, both in skeletal muscle (gas-
trocnemius and tibialis) and C2C12myocytes. Unexpectedly,
BCAAem was not able to counteract these effects (data not
reported). We cannot rule out that higher doses of amino
acids or different time intervals of treatment may be effective
both in the in vivo and in vitro context.
Equally important is that PGC-1a expression was mark-
edly increased in skeletal muscles by BCAAem in combi-
nation with Rvs (data not shown). In fact, the overexpression
of PGC-1a, a transcriptional coactivator that induces mito-
chondrial biogenesis and protects against muscle atrophy
(49), abrogates lovastatin-mediated atrogin-1 induction and
muscle damage both in mouse myocytes and in zebrafish
(30). Moreover, PGC-1a is required for the induction of key
ROS-scavenging enzymes (54) and the avoidance of ROS-
mediated removal of mitochondria, at least during myogen-
esis (6). Upregulating endogenous antioxidant levels is a way
to increase cell resilience to stress stimuli (in our case, Rvs)
beside an index of mitohormesis (i.e., the strategy to augment
efficient mitochondria) (47). Again, induction of genes pro-
moting ROS detoxification has been found to follow also
UPRmt activation, which promotes mitochondrial homeo-
stasis and cell survival (48). Accordingly, our findings show
that BCAAem strengthened the Rvs-induced expression of
CLPP, the proteolytic subunit of the ClpXP complex (a major
mitochondrial protease), and HSP60 (a mitochondrial chap-
erone). Both maintain proteostasis and activate UPRmt (36).
The hypothesis that efficacy of BCAAem in preventing the
Rvs-induced muscle damage may be owed partly to poten-
tiation of the antioxidant effect of statins is in agreement with
the results reported by Bouitbir et al. (11). Ten days of ex-
ercise training of young rats was, indeed, found to increase
resistance of plantaris muscle to acute atorvastatin exposure,
and this was through combining the effects on mitochondrial
function and ROS production. Together, the cellular (pro-
teostasis) and molecular (ROS defense) effects could explain
the efficacy of BCAAem to prevent Rvs myopathy.
Moreover, the present work shows that Rvs increased
muscle expression and activity of BCKDH, the rate-limiting
enzyme of mitochondrial oxidative degradation of BCAAs,
and BCAAem strengthened these effects. BCAAs are ca-
tabolized mainly in muscle cells (52), where protein turnover
is linked to the BCAA catabolic rate (34). Digested BCAAs
end up in the bloodstream and are thus readily available for
skeletal muscle and other tissues (31). After removal of the
amino group by BCATm, carbon skeletons of BCAAs are
available for decarboxylation and oxidation to end products
that can enter the tricarboxylic acid cycle. The amino group
of BCAAs is transferred by BCATm to a-ketoglutarate to
form mitochondrial glutamate; thereafter, with different
enzymatic reactions, oxaloacetate, glutamine, and alanine
formation is increased in the cytoplasm. Interestingly, we
reported that both Rvs and BCAAem increased the circulat-
ing level of alanine and that these increments are additive
(15). Moreover, it is worthy to note that increased BCAA
supply and catabolism seem to promote lipid metabolism and
fatty acid oxidation associated with a lower risk for metabolic
disorders (31). Thus, our findings suggest that Rvs treatment
increases protein and amino acid catabolism in skeletal
muscles and this can add new insights on the mechanisms of
statin myopathy and its prevention. Indeed, a metabolomic
analysis has demonstrated that simvastatin changes plasma
levels of several amino acids, including threonine, alanine,
and phenylalanine, and their degradation products, and these
changes have been correlated with LDL cholesterol changes
in participants of the Cholesterol and Pharmacogenetics
study (58). The authors have suggested that amino acids play
an important role in the mechanism of action of simvastatin
and can contribute to the inter-individual variation of re-
sponse to statins.
Clinical relevance of our results is double. First, they sug-
gest that a dietary supplement of amino acids may allow
subjects prone to muscle wasting to tolerate statin therapy.
Even if with controversial findings, a growing number of ro-
dent and human studies suggest that BCAA-rich protein sup-
plementation has beneficial effects on several health- and
fitness-related factors, such as body composition, exercise
performance, muscle properties, and glucose control (1, 5, 16).
Specifically, BCAAem was found to ameliorate clinical fea-
tures and complications when administered to patients with
disorders of energy metabolism, such as sarcopenia, heart
failure, and chronic obstructive pulmonary disease, which are
accompanied by muscular damage (2, 3, 18, 19). Second, our
data suggest that protection from Rvs myopathy is obtainable,
combining simultaneously effects on mitochondrial biology
and protein balance. In fact, several approaches have been
proposed until now, including coenzyme Q and vitamins to
improve mitochondrial defects and quench ROS in myocytes
(38) or carnitine to ameliorate protein breakdown (4), yet
clinical trials have dismantled these choices (7, 20).
It is important to note that we have studied the effects of
only one statin and one amino acid mixture. Other statins and
formulas remain to be evaluated. However, deciding which
combination of amino acids is most beneficial in this case may
be an extremely difficult task. In silico strategies have been
reported, recently, to studywhether amino acid supplementation
might be beneficial for increasing muscle contractile protein
synthesis (43), yet more than seven amino acid combinations—
BCAAem contains 11 amino acids—could not be modeled by
the flux model for intrinsic complexity. Finally, further mech-
anisms modulated by BCAAem and potentially involved in its
beneficial effect warrant thorough experimental assessment.
In summary, we unveiled a protective effect of dietary
BCAAem on Rvs-induced myopathy. Improved protein
metabolism and oxidative stress underlie, at least in part, the
protective action of BCAAem. Hence, we propose that nu-
tritional agents able to regulate protein balance and mito-
chondrial function could be a promising strategy to prevent
statin myopathy in humans.
Materials and Methods
Animals and treatments
The experiments were conducted in accordance with Eu-
ropean Community Guidelines and Italian Ministry of Health,
complied with The National Animal Protection Guidelines,
and approved by the Institutional Animal Ethics Committee.
C57BL/6JN male mice (8 weeks old, n= 80) from Charles
River were housed in a quiet room with controlled tempera-
ture, humidity, and 12-h light/12-h dark cycle and fed with
normal chow diet (Laboratorio Dottori Piccioni) (Table 1)
(15). Mice were treated with Rvs (20mg/kg/day, n= 20) or
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BCAAem alone (1.5mg/g BW/day, n= 20) or in combination
(Rvs + BCAAem, n= 20) with drinking water for 1 month.
BCAAem was dissolved in tap water by calculating average
daily drinking 2 weeks before starting treatment. The control
group received drinking water without any drug or supplement
(untreated; n= 20). BCAAem composition, relative percent-
age, and dietary intake of each amino acid are reported in
Table 1. The amino acid concentration used was previously
found to be active in rodents and mimics the recommended
daily dose for humans (16, 45). The dose of Rvs was that
normally used in hypercholesterolemic animal models (24,
40). Mice were killed by cervical dislocation, and whole
gastrocnemius, soleus, vastus lateralis, and tibialis anterior
muscles were rapidly collected and processed for the following
analysis (see below). Owing to the limited amount of available
material from specificmuscles and aimed to investigate overall
protective mechanisms of BCAAem supplementation without
an a priori hypothesis, we carried out a series of experiments in
different muscles (as summarized in Supplementary Table S2).
On the contrary, only to evaluate any potential effect of
BCAAem on the cholesterol-lowering capacity of Rvs, a
separate group of 8-week-old Apo-E KO mice (n= 40), on a
mixed 129SvJ and C57BL/6 background (Jackson Labs), were
fed on HFD (60% kcal fat) (D12492; Research Diets, Inc.) for
12 weeks and then administered with Rvs and BCAAem fol-
lowing the same schedule described above. Mice had ad libi-
tum access to tap water and food.
Plasma analysis
Blood samples were collected between 9:00 and 10:00
a.m. from the retro-orbital sinus. Total cholesterol and TGs
were analyzed in ApoE-KO fed mice with HFD using com-
mercially available enzymatic kits (Sentinel Diagnostic).
Serum CK level was determined in C57BL/6JN mice using
specific kit (Diagnostic Chemicals Limited).
Muscle fiber size and morphometry evaluation
Damage of myocyte nuclei was evaluated by toluidine blue
staining in whole gastrocnemius muscle. Morphometric
analysis was performed in serial transverse sections (10 lm
thick) cut with a Leica CM1850 cryostat and stained with HE.
Fiber CSA of gastrocnemius and vastus lateralis muscle was
evaluated on 150 fibers/muscle (n = 5 mice/group) by using
an Image 1.63 software (Scion Corporation).
Transmission electron microscopy
Whole gastrocnemius was cut into pieces (1mm3) and
placed in ice-cold fixative (2.5% glutaraldehyde and 2%
Table 1. Normal Chow Diet and BCAAem Composition and Dietary Intake
Nutrient Percent Amino acid
NCD BCAAema
D Dietary
intakePercentb
Dietary
intakec Percentb
Dietary
intaked
Macronutrient composition
raw protein 18.8 Arginine 1.15 0.058 — — —
Histidine 0.48 0.024 2.70 0.064 0.040
Isoleucine 0.80 0.040 15.60 0.274 0.234
Leucine 1.50 0.075 30.50 0.532 0.457
Lysine 1.05 0.053 13.20 0.251 0.198
Methionine+cysteine 0.75 0.038 5.40 0.119 0.081
Phenylalanine 0.90 0.045 1.60 0.069 0.024
Threonine 0.75 0.038 10.80 0.200 0.162
Tryptophan 0.23 0.012 0.20 0.015 0.003
Valine 1.00 0.050 19.60 0.344 0.294
Crude fat 4.3
Carbohydrate 76.9
Micronutrient composition (mg/kg)
Vitamin A 12,000UI Folic acid 2
Vitamin D 1000UI Choline chloride 1000
Vitamin E 40 Biotin 0.10
Vitamin B1 8 Iron 100
Vitamin B2 10 Cobalt 0.25
Vitamin B6 10 Copper 3
Pantothenic acid 15 Manganese 55
Vitamin K 1 Iodine 0.80
Vitamin PP 40 Zinc 50
Vitamin B12 0.02 dl-methionine 500
aMice were supplemented with BCAAem in drinking water (1.5mg/g bw/day, for 1 month).
bAmino acid contents are reported as g/100 g food/mouse.
cDietary amino acid intake (g/day) of mice on normal chow diet is determined on average daily food intake.
dDietary amino acid intake (g/day) of mice supplemented with BCAAem is determined on average daily water intake.
BCAAem, branched-chain amino acid-enriched mixture.
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paraformaldehyde in 0.1M sodium cacodylate buffer, pH 7.4)
for 5 h. Samples were then washed with 0.1 M sodium caco-
dylate buffer, postfixed for 2 h with 2% OsO4, dehydrated in
ethanol, block-stained with uranyl acetate, and embedded in
Epon 812 epoxic mixture as reported (15). Ultrathin sections
were double stained with uranyl acetate and lead citrate and
examined with a Philips CM10 transmission electron micro-
scope. Morphometric analysis of mitochondria was performed
as described (67). Randomly selected areas of tissue derived
from two animals/group were photographed at a magnification
of 5200· and analyzed with NIH Image software.
In vivo muscle function assessment
Exercise capacity was assessed in C57BL/6JN mice as
previously described (16, 17). Animals were placed on the
belt of a 6-lane motorized treadmill (Exer 3/6 Treadmill;
Columbus Instruments) supplied with shocker plates (elec-
trical stimulus: 200ms, 0.34mA, 1Hz repetition rate). After
acclimatization, mice were subjected to exhaustion treadmill
tests at 0 (horizontal treadmill) or to +5 (uphill treadmill)
inclination according to the protocol: 5min at 5m/min, fol-
lowed by incremental increase of speed of 1m/min every
minute until exhaustion. Exhaustion was defined as spending
time on the shocker plate without attempting to re-engage the
treadmill within 20 s. Three tests were performed on each
animal, allowing 4 days between each test.
Ex vivo functional assessment
Mechanical analysis was performed as described (17). The
tibialis anterior muscle of the right leg was dissected, placed in
an organ bath filled with Krebs solution (NaCl 120mM, KCl
2.4mM, CaCl2 2.5mM, MgSO4 1.2mM, glucose 5.6mM,
KH2PO4 1.2mM, NaHCO3 24.8mM, pH 7.4), bubbled with
95% O2 and 5% CO2 at 22C, and attached to a force trans-
ducer (Radnoti Organ Bath System; AD Instruments). Elec-
trical pulses were delivered through platinum electrodes
connected to a stimulator (Harvard Apparatus). Tetanic iso-
metric contractions were evoked (110Hz, 500ms, supramax-
imal amplitude) at Lo (length at which the maximal isometric
force is observed), and the fatigue index was determined from
the drop in force of the maximal absolute tetanic force fol-
lowing 20 repeated contractions in a ramp protocol at 0.03,
0.09, and 0.3Hz. Specific tetanic force is expressed as the
normalization of tetanic force over muscle volume. Fatigue
index was measured as the tetanic force drop for different
stimulation frequencies (from 0.03 to 0.9Hz, 500ms) com-
pared with the maximal tetanic force and expressed as percent.
C2C12 cell cultures and treatments
C2C12 myoblasts (<6 passages; ATCC, Manassas, VA)
were maintained at 37C, 5% CO2, and cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum, 1% penicillin/streptomycin, 1% l-
glutamine, and 1% Na+-pyruvate (EuroClone). Cells were
differentiated (C2C12 myocytes) by switching to differenti-
ation medium (DMEM containing 2% horse serum) that was
changed daily (27). After 5 days of differentiation, C2C12
myocytes were exposed to Rvs solubilized in sterilized water
as appropriate. BCAAem, dissolved in fresh differentiation
medium, was added at 1% (1· ) for 24 h.
Quantitative real-time polymerase chain reaction
RNA was isolated from muscle or C2C12 myocytes using
the RNeasy Mini Kit (Qiagen) and cDNA was synthesized
using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories)
as described (15). The gene (primer sequences in Table 2)
relative level was calculated as 2-DDCT, in which DDCT
corresponded to the difference between the DCT of either
treatment and the DCT of the untreated group.
Immunoblot analysis
Protein extracts were obtained from muscle or C2C12
myocytes using T-PER or M-PER Mammalian Protein Ex-
traction Reagent (Pierce; ThermoScientific) as indicated by
the manufacturer in the presence of protease and phosphatase
inhibitor cocktail (Sigma-Aldrich). Protein content was de-
termined with bicinchoninic acid protein assays (Pierce). An
appropriate amount of protein was run on sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
under reducing conditions. The proteins were revealed with
specific antibodies, anti-Atrogin-1 (Santa Cruz) at 1:250 di-
lution; anti-BCKDHA (LS Bio), anti-BCKDK, anti-CLPP,
and anti-p47phox (from Sigma-Aldrich); anti-SOD1, anti-
SOD2, anti-Catalase, and anti-BCATm (from Santa Cruz);
anti-Rac1 (Millipore); anti-gp91phox (BectonDikinson); and
anti-HSP60 (Cell Signaling; EuroClone) at 1:1000 dilution.
Anti-GAPDH at 1:10,000 dilution (Cell Signaling) was used
as loading control. When the Western blot membranes were
used for more than one protein, filters were stripped with the
Restore Western Blot Stripping Buffer (Pierce) and re-
incubated with the secondary antibody as suggested by the
manufacturer. The amount of protein was measured using
SuperSignal Substrate (Pierce) and densitometrically quan-
tified with an IMAGEJ software image analyzer.
De novo protein synthesis
C2C12 myocytes were exposed to puromycin (1lg/ml;
Sigma-Aldrich) solubilized in phosphate-buffered saline to
measure the de novo synthesis of proteins, as described (50).
After 10min of incubation, cells were harvested and proteins
were extracted as reported above. Puromycin incorporationwas
measured by separating 30lg of denaturated proteins by SDS-
PAGE. Total puromycin was revealed with an anti-puromycin
antibody (Millipore) at 1:2000 dilution. Anti-vinculin (Sigma-
Aldrich) at 1:10,000 dilution was used for normalization.
Branched-chain amino acid catabolism
The BCATm activity was measured spectrophotometri-
cally (340 nm) in cells (14). The samples were homogenized
in ice-cold buffer containing 0.4% CHAPSO (Sigma-
Aldrich) for the extraction of the enzyme from mitochondrial
matrix. After freeze/thawing, cells were centrifuged and the
supernatant was used as source of BCATm. The BCKDH ac-
tivity was evaluated using a-ketoisocaproate (Sigma-Aldrich)
as substrate as indicated in Nakai et al. (39). Cells were ho-
mogenized in ice-cold buffer containing 3% Triton X-100
(Sigma-Aldrich) to extract the enzyme. BCKDH activity was
determined spectrophotometrically (355nm) by measuring
the rate of NADH production resulting from the conversion of
a-ketoisovalerate to isobutyryl-CoA.
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Oxygen consumption
Oxygen consumption was measured as described (42, 62).
C2C12 myocytes were resuspended in Hank’s balanced salt
solution. Samples were analyzed at 37C in a gas-tight vessel
equipped with a Clark-type oxygen electrode (Rank Brothers
Ltd.) connected to a chart recorder. The oxygen electrode was
calibrated assuming the concentration of oxygen in the in-
cubation medium as 200lmol/l at 37C.
ATP and CS activity measurements
ATP amount was measured by using specific kit (Mole-
cular Probes; ThermoScientific). ATP was extracted by in-
cubating cells with 1% trichloroacetic acid in 4mmol/l
EDTA solution, 10min on ice. The extracts were centrifuged
(12,000 g, 10min, 4C) and used for ATP determination as
indicated by the manufacturer. CS activity was measured
spectrophotometrically (412 nm) at 30C as previously de-
scribed (56). Muscle tissue or cells were homogenized and a
buffer containing 0.1mmol/l 5,5-dithio-bis-(2-nitrobenzoic)
acid, 0.5mmol/l oxaloacetate, 50 lmol/l EDTA, 0.31mmol/l
acetyl-CoA, 5mmol/l triethanolamine hydrochloride, and 0.1
M Tris-HCl, pH 8.1 was added. CS activity was expressed as
nmol/min/mg of protein.
Mitochondrial oxidative stress
As described in Ref. (16), mitochondria were isolated from
muscle using the Qproteome Mitochondria isolation kit
(Qiagen). Mitochondrial protein content was determined
with BCA assay and 70 lg of mitochondrial proteins was
used per sample. Mitochondrial H2O2 release was measured
in the presence of horseradish peroxidase (HRP), using the
Amplex Red Hydrogen Peroxide/Peroxidase Assay kit
(Molecular Probes). In the presence of specific substrates,
which act as hydrogen donors, the action of HRP converts
colorless or nonfluorescent molecules into colored and/or
fluorescent moieties, respectively. Amplex Red is a substrate
for use with HRP-containing assays. Amplex Red, in the
presence of peroxidase enzyme, reacts with H2O2 in a 1:1
stoichiometry to produce resorufin, a red fluorescent com-
pound that has an absorption and fluorescence emission
maxima of 563 and 587 nm, respectively. Fluorometric
measures were made using a Fusion Universal Microplate
Analyzer (Packard/PerkinElmer) with excitation filter at
550 nm and emission filter at 590 nm. H2O2 production,
calculated from a standard curve, was expressed as nmol/
min/mg protein (16). Aconitase activity was measured in a
medium containing 30mM sodium citrate, 0.6mM MnCl2,
0.2mM NADP, 50mM Tris-HCl, pH 7.4, and 2U of iso-
citrate dehydrogenase. The formation of NADPH was fol-
lowed spectrophotometrically (340 nm) at 25C as described
(33). The level of aconitase activity measured equals active
aconitase (basal level). Aconitase inhibited by ROS in vivo
was reactivated so that total activity could be measured by
incubating mitochondrial extracts in a medium containing
50mM dithiothreitol, 0.2mM Na2S, and 0.2mM ferrous
ammonium sulfate. To assay lipid peroxidation in vastus
lateralis muscle, malondialdehyde (MDA) derived from
polyunsaturated fatty acid peroxides was evaluated by means
of the LPO-586 colorimetric assay kit (OxisResearch). Next,
to measure the oxidative damage of mitochondrial and nu-
clear DNA, the highly sensitive 8-OHdG Check ELISA Kit
( JalCA) was used in vastus lateralis. Measurements were
carried out in accordance with the manufacturer’s protocol.
Table 2. Primers Used for PCR Analysis
Gene Primer sequences PCR product (bp) Ta (C)
Atrogin-1 Sense 5¢-CTTCAACAGACTGGACTTCTCGA-3¢ 77 60
Antisense 5¢-CAGCTCCAACAGCCTTACTACGT-3¢
BCAT Sense 5¢-AGGTGGGACTGGAGACTGCA-3¢ 108 60
Antisense 5¢-TTGCCGTACAGCCACAGGAC-3¢
BCKDH Sense 5¢-GCCATCTCCACACCAACCTC-3¢ 101 60
Antisense 5¢-ACATCGTTGCCGTCCACAC-3¢
BCKDK Sense 5¢-CCCGAATCAACCCCCTCTTC-3¢ 127 60
Antisense 5¢-TGCAGGGAGCCACCAAGATAC-3¢
SOD1 Sense 5¢-GGCTTCTCGTCTTGCTCTC-3¢ 153 60
Antisense 5¢-AACTGGTTCACCGCTTGC-3¢
SOD2 Sense 5¢-GCCTCCCAGACCTGCCTTAC-3¢ 131 63
Antisense 5¢¢-GTGGTACTTCTCCTCGGTGGCG-3¢
Catalase Sense 5¢-CACTGACGAGATGGCACACTTTG-3¢ 173 63
Antisense 5¢-TGGAGAACCGAACGGCAATAGG-3¢
p47phox Sense 5¢-TGGTGGGTGGTCAGGAAAGG-3¢ 146 60
Antisense 5¢-CTCTGTGCGTTGCGGATGG-3¢
gp91phox Sense 5¢-GAGTGGTGTGAATGCCAGAGTC-3¢ 165 60
Antisense 5¢-TGTGATCCCAGCCAACCGAGTC-3¢
Rac1 Sense 5¢-ACTAAGTTGCGTTGTGCTGAG-3¢ 141 60
Antisense 5¢-AAGGAGGCTGTGCTGTGTC-3¢
GAPDH Sense 5¢-AACTTTGGCATTGTGGAAGG-3¢ 183 60
Antisense 5¢-ACACATTGGGGGTAGGAACA-3¢
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PCR, polymerase chain reaction; SOD, superoxide dismutase; Ta, temperature
of annealing.
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Muscle mitochondria and nuclei were isolated after homog-
enization of the tissue in an isolation medium comprising
220mM mannitol, 70mM sucrose, 20mM Tris-HCl, 1mM
EDTA, 5mM EGTA, and 5mM MgCl2, pH 7.4 (all from
Sigma-Aldrich). After centrifugation of samples at 700 g 4C,
the nuclear fraction was isolated, whereas the supernatants
were collected and transferred into new tubes for subsequent
centrifugation at 10,000 g, 4C, to obtained mitochondrial
fraction.Mitochondrial and nuclear DNAwas extracted using
QIampDNAMiniKit (Qiagen) and digestedwith nuclease P1
and alkaline phosphatase (Sigma-Aldrich). The quality and
quantity of DNA were confirmed by a NanoDrop ND-1000
spectrophotometry analysis. Absorbance of the ELISA
product of reaction was determined spectrophotometrically
using 450 nm as the primary wave.
Statistical analyses
All values are expressed as mean – standard error of the
mean. Student’s t-test was used to evaluate differences be-
tween two groups (as indicated). Analyses on four groups were
performed using two-way ANOVA, followed by Bonferroni
post-hoc test for multiple comparisons (GraphPad Prism).
Statistical significance was set at p-value <0.05.
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Abbreviations Used
3-MeH¼ 3-methylhistidine
8-OHdG¼ 8-hydroxy-2¢-deoxyguanosine
ApoE-KO¼ apolipoprotein E gene-deficient
BCAA¼ branched-chain amino acid
BCAAem¼ branched-chain amino acid-enriched mixture
BCATm¼mitochondrial branched-chain
aminotransferase
BCKDH¼ branched-chain a-keto acid dehydrogenase
BCKDK¼ branched-chain a-keto acid dehydrogenase
kinase
BW¼ body weight
CK¼ creatine kinase
CLPP¼ caseinolytic peptidase ATP-dependent
proteolytic subunit homolog
CS¼ citrate synthase
CSA¼ cross-sectional area
DMEM¼Dulbecco’s modified Eagle’s medium
GAPDH¼ glyceraldehyde-3-phosphate dehydrogenase
HE¼ hematoxylin–eosin
HFD¼ high-fat diet
HSP60¼ heat shock protein 60
MAFbx¼muscle atrophy F-Box
MDA¼malondialdehyde
mTOR¼mechanistic/mammalian target of rapamycin
MW¼muscle weight
PGC-1a¼ peroxisome proliferator-activated receptor
gamma coactivator-1 a
phox¼ phagocyte oxidase
Rac1¼Ras-related C3 botulinum toxin substrate 1
Rvs¼ rosuvastatin
ROS¼ reactive oxygen species
SDS-PAGE¼ sodium dodecyl sulfate–polyacrylamide
gel electrophoresis
SOD¼ superoxide dismutase
T-Cho¼ total cholesterol
TG¼ triglyceride
UPRmt ¼mitochondrial unfolded protein response
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